Person:
ÜNDER, DUYGU

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÜNDER

First Name

DUYGU

Name

Filters

2021 - 20243
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Combinatorial Usage of Sumac Unriped Fruit Extract (Rhus Coriaria) and Tannic Acid Enhanced Synergistic Anti-Angiogenic Effect on Chick Chorioallantoic Membrane Assay
    (ISTANBUL UNIV-CERRAHPASA, 2021-02-01) ÜNDER, DUYGU; Uvez, Ayca; Kilic, Sima; Esener, O. B. Burak; Under, Duygu; Saltan, Fatma Zerrin; Dimas, Konstantinos; Armutak, Elif Ilkay
    Rhus coriaria (sumac) naturally grows worldwide and contains many phytochemicals. Tannic acid is frequently used for treating medical conditions. The aim of this study is to determine the synergistic effects of methanolic and acetonic extracts of Rhus coriaria's from unriped fruits in combination with tannic acid on angiogenesis by using the Chick Chorioallantoic Membrane (CAM) assay. The effects of methanol and acetone extracts of Sumac (MES and AES, respectively, at a final concentration of 5 mg/mL for both) and tannic acid (Tan 1.25 and 5 mg/mL) alone or in combination were examined for their effect on angiogenesis by applying the CAM assay. CAM assay results showed that AES is more effective than MES on suppressing angiogenesis. Tannic acid started to show antiangiogenic effects at the concentration of 5 mg/mL. When AES and tannic acid were used in combination at a dose of 5 mg/mL each, a very strong antiangiogenic effect was observed (score; 1.1 +/- 0.131, p<0.001). The combinatorial usage of AES and tannic acid may result in strong suppression of angiogenesis, an effect that is shown in this study for the first time. Based on this observation, combinatorial usage of sumac extracts and tannic acid could be promising as a new antiangiogenic therapy.
  • No Thumbnail Available
    PublicationMetadata only
    Hastanede yatan kesin veya olası COVID-19 hastalarında klinik eczacı öncülüğünde yürütülen ilaç incelemesi hizmeti
    (2022-03-12) ÜNDER, DUYGU; DEMİRCİ, MUHAMMED YASİR; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; ÜNDER D., ENVER C., DEMİRCİ M. Y. , AYHAN Y. E. , ÖZGAN B., İLERLER E. E. , OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.
  • No Thumbnail Available
    PublicationMetadata only
    Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic
    (2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.
    Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.